Close X
Attorney Spotlight

How did an interest in healthcare policy lead Robert Platt to a career in the law? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Proxy Season and Form 10-K Filings: A Look Back at 2015 and What to Expect in 2016

Publications

December 21, 2015

This overview summarizes new disclosure requirements and other developments that will generally be applicable to SEC reporting companies in connection with their upcoming proxy statement and Form 10-K filings, including those with respect to the executive compensation and corporate governance provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the "Dodd-Frank Act"). Here are the highlights:

SEC New Disclosure Requirements, Proposed Rules and Recent Developments

  • Long anticipated CEO pay ratio disclosure rule
  • Proposed anti-hedging and anti-pledging disclosure for employees/directors 
  • Proposed additional pay-for-performance table- value to compensation presentation 
  • Proposed new incentive compensation clawback policies under certain accounting restatements 

2016 Season ISS and Glass Lewis Updates

ISS

  • Reduction of acceptable number of board positions for non-CEO directors
  • Continual "against" recommendation for the election of existing directors of existing public companies in unilateral bylaw/charter amendments

Glass Lewis

  • New guidance for overboarding
  • Contextual evaluation of certain exclusive forum provisions
  • New scrutiny of chair of nominating committee for regular board assessment and refreshment in context of company "poor performance"
  • Explicit voting guidelines "against" directors for failures in environmental and social risk oversight
  • New examination structure for evaluating conflicting management and shareholder proposals

Public Company Accounting Oversight Board (PCAOB)

  • Preparations for increased audit scrutiny in response to the full effect of Auditing Standard No. 18, Related Parties

To read more about these developments and expectations for the upcoming proxy season, download the complete alert.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.